ERBB2 and breast carcinoma: Several biomarkers, including the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 are routinely used to classify breast cancer subtypes in the clinic [3,4].